<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04369547</url>
  </required_header>
  <id_info>
    <org_study_id>REB20-0196</org_study_id>
    <nct_id>NCT04369547</nct_id>
  </id_info>
  <brief_title>Roflumilast TMS-EEG Plasticity</brief_title>
  <official_title>A Double-blind Placebo-controlled Crossover Study of Roflumilast Synaptic Plasticity Enhancement: a TMS-EEG Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Repetitive transcranial magnetic stimulation (rTMS) uses a magnetic field to non-invasively&#xD;
      induce electrical function within the brain. Stimulation allows brain cells to change the way&#xD;
      that they adapt and communicate with each other, known as 'synaptic plasticity'. It is&#xD;
      thought that alterations in these adaptive brain changes underlie the ability of rTMS to&#xD;
      treat mental illnesses like depression. rTMS is a Health Canada approved treatment for&#xD;
      depression, however, 2/3rds of people fail to show meaningful improvement. This highlights&#xD;
      the need for more effective therapeutic means. The purpose of the present study is to augment&#xD;
      the therapeutic abilities of rTMS through the conjunctive use of a medication that also&#xD;
      increases synaptic plasticity. We will pair TMS with an electroencephalograph (EEG) to&#xD;
      measure activity dependent changes in the frontal cortex following rTMS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, placebo-controlled, crossover trial will enroll 20 healthy participants. In&#xD;
      one arm of the study, participants will randomly receive either 250mcg of roflumilast (a&#xD;
      phosphodiesterase-4 inhibitor), or a placebo capsule, and participants will receive the other&#xD;
      intervention one week later.&#xD;
&#xD;
        1. The investigators will recruit 20 healthy participants through community advertisement,&#xD;
           carefully screened for exclusion factors related to rTMS and roflumilast.&#xD;
&#xD;
        2. Participants will be randomly assigned by random number sequence with allocation&#xD;
           concealment to one of two first arms of the crossover study: a) placebo-roflumilast&#xD;
           250mcg and b) roflumilast 250mcg-placebo.&#xD;
&#xD;
        3. Participants will complete the QIDS-SR (Quick Inventory of Depressive Symptoms-Self&#xD;
           Report), the BAI (Beck Anxiety Inventory), and the STAI (State Trait Anxiety Inventory).&#xD;
&#xD;
           Participants will report their perception of physical symptoms (potential side effects)&#xD;
           in the 7 days before participating in the study taking the randomized capsule (Toronto&#xD;
           Side Effects Scale - 1 Week).&#xD;
&#xD;
        4. Participants will take their blinded capsule at least 30 minutes prior to TBS&#xD;
           (theta-burst stimulation).&#xD;
&#xD;
        5. The resting motor threshold of participants will be determined using electromyographic&#xD;
           electrodes (EMG). EMG electrodes will be positioned over the first dorsal interosseous&#xD;
           (FDI) muscle on the right hand. These electrodes are non-invasive and use an adhesive to&#xD;
           stick to the skin.&#xD;
&#xD;
        6. The M1 hand strip will be localized using single pulse TMS (MagPro X100) in conjunction&#xD;
           with neuronavigation and an atlas brain.&#xD;
&#xD;
        7. Muscle activation in response to TMS will be measured through motor evoked potentials&#xD;
           (MEP). The strength of MEPs in response to differing strengths of single pulse TMS will&#xD;
           be used to determine a participants resting motor threshold (RMT). The RMT is the lowest&#xD;
           TMS setting at which the FDI muscle responds to TMS stimulus. 80% of the RMT will then&#xD;
           be the strength at which TBS protocol will be applied to the DLPFC.&#xD;
&#xD;
        8. Two baselines of TMS Evoked Potentials (TEPs) will be collected via one hundred&#xD;
           single-pulse (120% RMT), 0.25Hz) over the F3 site. Each baseline will occur 10 minutes&#xD;
           apart.&#xD;
&#xD;
        9. TBS-rTMS will be applied to the DLPFC site. TBS consists of 2s trains every 10s. Each&#xD;
           train is composed of 3 pulses at 50Hz, 200ms intervals given at 80% RMT. The total time&#xD;
           for this treatment stimulus is 600 pulses over 190s.&#xD;
&#xD;
       10. Following TBS, one hundred TEPs over the F3 site will again be acquired at 10, 20, and&#xD;
           30 minutes after treatment (single pulse, 120%RMT, 0.25Hz).&#xD;
&#xD;
      As this is a cross-over study, participants will return 1 week later to repeat the second arm&#xD;
      of the protocol (steps 3-10).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TMS Evoked Potential amplitude</measure>
    <time_frame>Baseline versus 10, 20, and 30 minutes following theta-burst stimulation.</time_frame>
    <description>Change in the electrical response of neurons in the dorsolateral prefrontal cortex will be recorded.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Synaptic Plasticity</condition>
  <arm_group>
    <arm_group_label>Roflumilast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will ingest a capsule containing 250mcg of the phosphodiesterase-4 inhibitor roflumilast. Their baseline TMS evoked potentials (TEP) will be recorded over 100 single TMS pulses prior to receiving theta-burst stimulation (TBS; a patterned stimulation) to the left dorsolateral prefrontal cortex (DLPFC). TEP will then be re-recorded at 10, 20, and 30 minutes post-stimulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will ingest a capsule identical to that containing the study medication, however, this capsule will be contain a placebo. Their baseline TEP will be recorded over 100 single TMS pulses prior to receiving TBS to the left DLPFC. TEP will then be re-recorded at 10, 20, and 30 minutes post-stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial Magnetic Stimulation</intervention_name>
    <description>Single-pulse transcranial magnetic stimulation and theta-burst stimulation.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Roflumilast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
    <description>Roflumilast 250mcg</description>
    <arm_group_label>Roflumilast</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo capsule matched to roflumilast capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy individuals (no chronic medical conditions).&#xD;
&#xD;
          2. Aged 18-60 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy&#xD;
&#xD;
          2. Lactation&#xD;
&#xD;
          3. Epilepsy&#xD;
&#xD;
          4. Previous stroke&#xD;
&#xD;
          5. Current Renal Disease&#xD;
&#xD;
          6. Current Liver Disease&#xD;
&#xD;
          7. Allergy to roflumilast or any of its non-medicinal ingredients&#xD;
&#xD;
          8. Current psychiatric concerns&#xD;
&#xD;
          9. Currently taking any medications that interact with roflumilast&#xD;
&#xD;
         10. Intracranial metallic objects (dental hardware is not an exclusionary criterion)&#xD;
&#xD;
         11. Substance use disorder&#xD;
&#xD;
         12. The inability to refrain from alcohol use for 24 hours prior to stimulation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander McGirr, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander McGirr, MD PhD</last_name>
    <phone>4032106410</phone>
    <email>alexander.mcgirr@ucalgary.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N1N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexander McGirr, MD PhD</last_name>
      <phone>4032106410</phone>
      <email>alexander.mcgirr@ucalgary.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>January 11, 2021</last_update_submitted>
  <last_update_submitted_qc>January 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Alexander McGirr</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>rTMS</keyword>
  <keyword>EEG</keyword>
  <keyword>Augmented Plasticity</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There will be no sharing of individual participant data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

